Pdb67 - Once-Weekly Semaglutide Versus Dulaglutide for the Treatment of Patients With Type 2 Diabetes in Portugal: A Long-Term Cost-Effectiveness Analysis Based on Sustain 7

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.772
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pdb87 - A Cost-Of-Control Analysis: Once-Weekly Semaglutide Reduces Cost of Reaching Treatment Targets in Patients With Type 2 Diabetes Mellitus in Norway

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Advances in Therapy
MedicinePharmacology
2020English

The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Common OAD: A Subgroup Analysis From SUSTAIN 2–4 and 10

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2020English

Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2014English

Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Pdb74 - Ideglira Versus Iglarlixi for Patients With Inadequately Controlled Type 2 Diabetes on Basal Insulin: A Long-Term Cost-Effectiveness Analysis in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy